4-propylhexanol methyl ether

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-propylhexanol methyl ether
• 英文别名: methyl-(4-propyl-cyclohexyl)-ether；Methyl-(4-propyl-cyclohexyl)-aether；4-Methoxy-1-propyl-cyclohexan；1-Methoxy-4-propylcyclohexane
• 化学式: C₁₀H₂₀O
• 分子量: 156.268
• InChiKey: VHOFVIBQLIHZFJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  4-烯丙基苯甲醚 在 镍 作用下， 150.0~220.0 ℃ 、7.84 MPa 条件下， 生成 4-propylhexanol methyl ether
  参考文献：
  名称：

  Gauthier, Annales de Chimie (Cachan, France), 1945, vol. <11> 20, p. 581,608

  摘要：

  DOI：

文献信息

• QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS
  申请人：CHAUDHARI Amita

  公开号：US20080293706A1

  公开（公告）日：2008-11-27

  Invented is a method of inhibiting the activity/function of PI3 kinases using quinoxaline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinoxaline derivatives.

  发明了一种使用喹喔啉衍生物抑制PI3激酶活性/功能的方法。还发明了一种通过给予喹喔啉衍生物来治疗自身免疫性疾病、炎症性疾病、心血管疾病、神经退行性疾病、过敏、哮喘、胰腺炎、多器官功能衰竭、肾脏疾病、血小板聚集、癌症、精子活动力、移植排斥、移植物排斥和肺部损伤等一种或多种疾病状态的方法。
• [EN] INHIBITORS OF Akt ACTIVITY<br/>[FR] INHIBITEURS DE L'ACTIVITE DE AKT
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2005011700A1

  公开（公告）日：2005-02-10

  Invented are novel 1 H-imidazo[4,5-c]pyridin-2-yI compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.

  发明了新型的1H-咪唑[4,5-c]吡啶-2-基化合物，这些化合物用作蛋白激酶B活性的抑制剂，并用于治疗癌症和关节炎。
• [EN] INHIBITORS OF AKT ACTIVITY<br/>[FR] INHIBITEURS DE L'ACTIVITE DE LA PROTEINE KINASE B (AKT)
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2005085227A1

  公开（公告）日：2005-09-15

  Invented are novel pyridine compounds, the use of such compounds as inhibitors of PKB/AKT kinase activity and in the treatment of cancer and arthritis.

  发明了新型的吡啶化合物，以及这些化合物作为PKB/AKT激酶活性的抑制剂以及用于治疗癌症和关节炎的用途。
• Rapid probing of the reactivity of P450 monooxygenases from the CYP116B subfamily using a substrate-based method
  作者：Ren-Jie Li、Jian-He Xu、Yue-Cai Yin、Nicolas Wirth、Jiang-Meng Ren、Bu-Bing Zeng、Hui-Lei Yu

  DOI：10.1039/c6nj00809g

  日期：——

  Four types ofO-methylated substrates were designed as probes for the detection of fingerprints of Type IV P450s.

  设计了四种O-甲基化底物作为探针，用于检测IV型P450的指纹。
• Thrombopoietin mimetics
  申请人：——

  公开号：US20040019190A1

  公开（公告）日：2004-01-29

  Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy- 1 -azobenzene derivative.

  发明了非肽类TPO类似物。还发明了用于制备目前发明的化合物的新工艺和中间体。还发明了一种治疗血小板减少症的方法，包括给予需要的哺乳动物，包括人类，有效量的选择性羟基-1-偶氮苯衍生物。